Premium
Regulatory sequences of H19 and IGF2 genes in DNA‐based therapy of colorectal rat liver metastases
Author(s) -
Ohana Patricia,
Schachter Pinhas,
Ayesh Basim,
Mizrahi Aya,
Birman Tatiana,
Schneider Tamar,
Matouk Imad,
Ayesh Suhail,
Kuppen Peter J. K.,
de Groot Nathan,
Czerniak Abraham,
Hochberg Abraham
Publication year - 2005
Publication title -
the journal of gene medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.689
H-Index - 91
eISSN - 1521-2254
pISSN - 1099-498X
DOI - 10.1002/jgm.670
Subject(s) - genetic enhancement , colorectal cancer , cancer research , diphtheria toxin , gene , transfection , toxin , biology , medicine , cancer , genetics
Background Malignant tumors of the liver are among the most common causes of cancer‐related death throughout the world. Current therapeutic approaches fail to control the disease in most cases. This study seeks to explore the potential utility of transcriptional regulatory sequences of the H19 and insulin growth factor 2 (IGF2) genes for directing tumor‐selective expression of a toxin gene (A fragment of diphtheria toxin), delivered by non‐viral vectors. Methods The therapeutic potential of the toxin vectors driven by the H19 and the IGF2‐P3 regulatory sequences was tested in a metastatic model of rat CC531 colon carcinoma in liver. Results Intratumoral injection of these vectors into colon tumors implanted in the liver of rats induced an 88% and a 50% decrease respectively in the median tumor volume as compared with the control groups. This therapeutic action was accompanied by increased necrosis of the tumor. Importantly, no signs of toxicity were detected in healthy animals after their treatment by the toxin expression vectors. Conclusions DT‐A was preferentially expressed in liver metastases after being transfected with H19 or IGF2‐P3 promoter‐driven DT‐A expression plasmids, causing a very significant inhibition of tumor growth as a result of its cytotoxic effect. Our findings strongly support the feasibility of our proposed therapeutic strategy, which may contribute to open new gene therapeutic options for human liver metastases. Copyright © 2004 John Wiley & Sons, Ltd.